Drug intelligence / Profile preview

ciprofloxacin + metronidazole + neomycin

Development stage
Phase 2
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

Ciprofloxacin + metronidazole + neomycin is a combination of three antibiotics, each with distinct mechanisms of action, used to treat mixed infections involving both aerobic and anaerobic bacteria. Ciprofloxacin is a second-generation fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, leading to the disruption of DNA replication and cell death[2]. Metronidazole is an antimicrobial agent effective against anaerobic bacteria and protozoa; it works by generating free radicals that damage microbial DNA[1][3]. Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis in susceptible bacteria[6]. This combination may be considered for complex or mixed infections where broad-spectrum coverage—including both aerobic and anaerobic organisms—is required. While combinations such as ciprofloxacin plus metronidazole or neomycin plus metronidazole are established in clinical practice (e.g., for colorectal surgery prophylaxis), there is limited evidence supporting the routine use of all three agents together.

02

Targets

DNA gyraseBacterial RibosomeTopo IV (Bacterial Topoisomerase IV)Neuraminidase

Beyond the preview

Go deeper on ciprofloxacin + metronidazole + neomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofloxacin + metronidazole + neomycin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call